GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$171.79
+2.58%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$171.99
From 52W high+0.00%
Volume893909.00
Market cap$213.08B
P/E (TTM)—
P/S (TTM)6.9x
Div yield1.43%
Key dataNov 4, 2026
Open
$171.99
From 52W high
+0.00%
Volume
893909.00
Market cap
$213.08B
ValuationView details →
P/E (Fwd)
19.8x
EV/EBITDA
282.9x
P/E (TTM)
—
RSI (14)
72.6
MomentumView details →
1D Return
+2.58%
YTD Return
+38.46%
SummaryUpdated Sep 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved a generic injectable version of lenacapavir for HIV prevention on November 2, 2026.15h agoGilead Sciences announced that it will participate in HIV Glasgow 2026 from November 8–11 and present results from more than 50 studies, including late-breaking clinical data and real-world evidence.2d ago